<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Nephrol</journal-id><journal-title-group><journal-title>BMC Nephrology</journal-title></journal-title-group><issn pub-type="epub">1471-2369</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24228847</article-id><article-id pub-id-type="pmc">3840610</article-id><article-id pub-id-type="publisher-id">1471-2369-14-252</article-id><article-id pub-id-type="doi">10.1186/1471-2369-14-252</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Cross-over study of influence of oral vitamin C supplementation on inflammatory status in maintenance hemodialysis patients</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Zhang</surname><given-names>KunYing</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>zhangky6159@163.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Li</surname><given-names>YinHui</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>liyinhui2008@hotmail.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Cheng</surname><given-names>XuYang</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>chengxuyang@medmail.com.cn</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Liu</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>liulimd@gmail.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Bai</surname><given-names>WenYing</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>brianbsbbc@126.com</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Guo</surname><given-names>WeiYa</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>gwy315@sina.cn</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Wu</surname><given-names>LeiYun</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>wly2992@126.com</email></contrib><contrib contrib-type="author" corresp="yes" id="A8"><name><surname>Zuo</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>ZuoLiMD@Gmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Medicine, Renal Division, Peking University First Hospital, Beijing, P. R. China</aff><aff id="I2"><label>2</label>Peking University Institute of Nephrology, Beijing, P. R. China</aff><aff id="I3"><label>3</label>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, P. R. China</aff><aff id="I4"><label>4</label>Department of Nephrology, Peking University People&#x02019;s Hospital, Beijing, P. R. China</aff><aff id="I5"><label>5</label>Jilin University Fourth Hospital, Changchun, Jilin, P. R. China</aff><aff id="I6"><label>6</label>Beijing Daxing district People&#x02019;s Hospital, Beijing, P. R. China</aff><aff id="I7"><label>7</label>Guangwai Hospital, Beijing, P. R. China</aff><aff id="I8"><label>8</label>Beijing No. 2 Hospital, Beijing, P. R. China</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>14</day><month>11</month><year>2013</year></pub-date><volume>14</volume><fpage>252</fpage><lpage>252</lpage><history><date date-type="received"><day>10</day><month>11</month><year>2012</year></date><date date-type="accepted"><day>5</day><month>11</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Zhang et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Zhang et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2369/14/252"/><abstract><sec><title>Background</title><p>Both vitamin C deficiency and inflammation are prevalent in maintenance hemodialysis (MHD) patients. In this study, we aimed to elucidate the effect of oral vitamin C supplementation on inflammatory status in MHD patients with low vitamin C level and high hypersensitive C-reactive protein (hs-CRP) level.</p></sec><sec><title>Methods</title><p>A total of 128 patients were recruited in our present study. Patients were divided into two groups. In group 1 (n&#x02009;=&#x02009;67), patients were orally administered with 200&#x000a0;mg/day vitamin C in the first 3&#x000a0;months, and then the vitamin C supplementation was withdrawn in the next 3&#x000a0;months. In group 2 (n&#x02009;=&#x02009;61), patients were not given vitamin C in the first 3&#x000a0;months, and then they were orally administered with 200&#x000a0;mg/day in the next 3&#x000a0;months. Levels of hs-CRP, prealbumin, albumin and hemoglobin as well as the EPO resistance index (ERI) were determined at the baseline and every 3&#x000a0;months throughout the study. Plasma vitamin C level was determined by high-performance liquid chromatography with UV detection.</p></sec><sec><title>Results</title><p>Among the 128 patients, 28 of them dropped out of the study before completion. Consequently, a total of 100 patients (group 1: n&#x02009;=&#x02009;48; group 2: n&#x02009;=&#x02009;52) were included in the final analysis. At the baseline, the plasma vitamin C level of all patients was less than 4&#x000a0;&#x003bc;g/mL. However, this proportion was decreased to 20% after the vitamin C supplementation for 3&#x000a0;months. Compared with patients without the vitamin C supplementation, a decreased level of hs-CRP and an increased level of prealbumin were induced by the vitamin C supplementation for 3&#x000a0;months in both groups. However, levels of these biomarkers returned to their original state after the supplementation was withdrawn. Same beneficial effects on plasma albumin, hemoglobin and ERI response to vitamin C supplementation were observed in the two groups without statistical significance.</p></sec><sec><title>Conclusions</title><p>The inflammatory status in MHD patients with plasma vitamin C deficiency and high levels of inflammatory markers could be partially improved by long-term oral administration of small doses of vitamin C.</p></sec><sec><title>Trial registration</title><p>The clinical trial number: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT01356433?term=vitamin+c+and+dialysis&#x00026;rank=2">NCT01356433</ext-link>.</p></sec></abstract><kwd-group><kwd>Hemodialysis</kwd><kwd>Inflammation</kwd><kwd>Vitamin C</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>The life expectancy of maintenance hemodialysis (MHD) patients is significantly lower than that of healthy subjects [<xref ref-type="bibr" rid="B1">1</xref>]. Atherosclerotic cardiovascular disease is the leading cause of death in this population. In addition to traditional cardiovascular risk factors, there are some non-traditional risk factors, including micro-inflammation [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Therefore, measures should be taken to correct the conditions with a possibly negative effect on arthrosclerosis.</p><p>Inflammation is prevalent in MHD patients. As an inflammatory marker, C-reactive protein (CRP) is an important sensitive acute phase reactant [<xref ref-type="bibr" rid="B4">4</xref>]. Previous investigations demonstrated that high level of serum CRP is a strong predictor of cardiovascular mortality both in healthy subjects [<xref ref-type="bibr" rid="B5">5</xref>] and MHD patients [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Vitamin C is one of the most important water soluble antioxidants. It is well established that the plasma vitamin C level is generally lower in MHD patients [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>] than that in general population, which is attributed to inadequate dietary intake, oxidative stress [<xref ref-type="bibr" rid="B9">9</xref>] and loss during dialysis session [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B10">10</xref>].</p><p>The low level of plasma vitamin C as well as inflammatory status has been recently reported to be closely related to the increased risk of cardiovascular morbidity and mortality in either MHD or peritoneal dialysis (PD) patients [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Our previous cross-sectional analysis showed that low level of plasma vitamin C is negatively associated with the CRP level [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>The hypothesis that the inflammatory status may be improved by vitamin C supplementation has been studied in a limited number of investigations based on a limited number of patients, resulting in conflicting results. One study was conducted on 33 MHD patients for 2&#x000a0;months [<xref ref-type="bibr" rid="B13">13</xref>], another one was conducted on 20 MHD patients for 2&#x000a0;months [<xref ref-type="bibr" rid="B14">14</xref>], and both studies did not get positive conclusions. However, an investigation documented that the 8-hydroxy-2&#x02032;-deoxyguanosine (8-OHdG) level of cellular DNA is reduced after the vitamin C supplementation for 8&#x000a0;weeks in chronic hemodialysis patients [<xref ref-type="bibr" rid="B15">15</xref>]. These previous conflicting results might be partly due to either limited sample size or short period of observation.</p><p>In the present study, we designed a randomized controlled cross-over study with relatively large sample size and aimed to investigate the effect of vitamin C supplementation on inflammatory status in MHD patients.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study patients</title><p>The effect of oral vitamin C supplementation on inflammatory status in MHD patients with low vitamin C level and high hypersensitive CRP (hs-CRP) level was investigated using a randomized controlled cross-over study. Patients who met all of the following inclusion criteria were included: (1) more than 18&#x000a0;years old; (2) under stable condition, receiving conventional hemodialysis for 4&#x02013;4.5&#x000a0;hours thrice weekly and MHD for at least 3&#x000a0;months; Kt/V&#x02009;&#x0003e;&#x02009;1.2; (3) plasma vitamin C level&#x02009;&#x0003c;&#x02009;4&#x000a0;&#x003bc;g/mL and hs-CRP level&#x02009;&#x0003e;&#x02009;3&#x000a0;mg/L; (4) not receiving any form of vitamin C supplementation within 3&#x000a0;months prior to the investigation. Patients with any one or more exclusion criteria were excluded from the investigation: (1) either hepatitis B surface antigen positive, hepatitis C antibody positive or HIV carrier; (2) acute infection within 1&#x000a0;month prior to the investigation; (3) neoplasm, hemopathy or active autoimmune disease; (4) use of steroids and/or immunosuppressive agents within 3&#x000a0;months prior to the investigation; (5) pregnancy or breast feeding.</p><p>In the present study, 128 MHD patients were recruited from five dialysis facilities in North China. The mean age and the mean dialysis vintage of the patients were 64.1&#x02009;&#x000b1;&#x02009;12.1&#x000a0;years and 50.6&#x02009;&#x000b1;&#x02009;32.5 [median 48, inter-quartile range (IQR) 21, 72] months, respectively. Patients were divided into two groups as follows. In group 1 (n&#x02009;=&#x02009;67), patients were orally administered with 200&#x000a0;mg/day vitamin C in the first 3&#x000a0;months, and then the vitamin C supplementation was withdrawn in the next 3&#x000a0;months. In group 2 (n&#x02009;=&#x02009;61), patients were not given vitamin C in the first 3&#x000a0;months, and then they were orally administered with 200&#x000a0;mg/day vitamin C in the next 3&#x000a0;months. No patient was provided with omega-3 and/or vitamin E. Levels of plasma vitamin C, hs-CRP, prealbumin, albumin and biochemical parameters of interest were determined at the baseline and every 3&#x000a0;months throughout the study.</p><p>This study was approved by the Ethics Committee of Clinical Research, Peking University First Hospital (clinical trial number: NCT01356433). Written informed consent was obtained from all participants.</p></sec><sec><title>Sample collection and laboratory measurements</title><p>Fasting blood samples were collected from MHD patients through the arteriovenous fistula just before dialysis session. Collected blood samples were transported to the laboratory using heparin-containing tubes in an ice bath. Plasma was separated by centrifugation (2,000&#x000a0;g, 10&#x000a0;min) at 4&#x000b0;C within 30&#x000a0;min. An aliquot of 200&#x000a0;&#x003bc;L plasma was immediately mixed with 200&#x000a0;&#x003bc;L of 10% metaphosphoric acid (MPA) due to the instability of vitamin C in plasma, and the mixture was then stored at &#x02212;80&#x000b0;C until further analysis within 2&#x000a0;weeks.</p><p>Vitamin C level was determined by high-performance liquid chromatography (HPLC) (Agilent 1100 series, Agilent Technologies, USA) on a Diamonsil C18 column (150&#x000a0;mm&#x02009;&#x000d7;&#x02009;4.6&#x000a0;mm, 3&#x000a0;&#x003bc;m) with UV detection according to the previously described method [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. Intra-assay and inter-assay coefficients of variation were 2.7% and 2.5%, respectively. The reference vitamin C level in normal population ranges from 4 to 14&#x000a0;&#x003bc;g/mL [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>].</p><p>EPO resistance index (ERI) was defined as the ratio of the dosage of recombinant human erythropoietin (rHuEpo) (IU/kg/week) and the concentration of hemoglobin (g/dl) on the day of plasma sampling. The hs-CRP level was determined using the immunonephelometric assay (First Chemical Pharmaceutical Co., Japan) with a detection limit of 0.1&#x000a0;mg/L. Levels of prealbumin, albumin, ferritin, calcium, serum bicarbonate, uric acid and hemoglobin were determined by standard techniques in the Clinical Laboratory of Peking University First Hospital, Beijing, China.</p><p>Patient baseline demographics, including age, gender, primary cause of end stage renal disease (ESRD), dialysis vintage and drug use, were also collected and recorded.</p></sec><sec><title>Statistical analysis</title><p>Normally distributed variables, such as albumin, prealbumin and hemoglobin, were expressed as mean&#x02009;&#x000b1;&#x02009;SD. Non-normally distributed variables, such as vitamin C and hs-CRP, were presented as median and IQR. Levels of albumin, prealbumin and hemoglobin between groups were compared using Student&#x02019;s <italic>t</italic>-test or one-way analysis of variance (one-way-ANOVA). Categorical variables between groups were compared using <italic>&#x003c7;</italic><sup>2</sup> test. Levels of vitamin C and hs-CRP between groups were compared using Mann&#x02013;Whitney test or Kruskal Wallis Test. Statistical analysis was performed using SPSS version 11.5 (SPSS, Inc., Chicago, IL, USA). A P value of less than 0.05 was considered as statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Demographics</title><p>Among the 128 patients, 28 of them dropped out of the study before completion as follows: four heart failure, three acute infection, two repeated hemafecia, two pancytopenia of unknown reason, one renal transplant, one bladder carcinoma, five non-compliance, one wound and surgery, two transferred to other facilities and seven death. Consequently, a total of 100 patients (group 1: n&#x02009;=&#x02009;48; group 2: n&#x02009;=&#x02009;52) were included in the final analysis (47 males, 53 females), with a mean age of 64.4&#x02009;&#x000b1;&#x02009;11.7&#x000a0;years and a median dialysis vintage of 48 (IQR 21, 72) months (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline characteristics of the study population (n&#x02009;=&#x02009;100)</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom"><bold>Item</bold><hr/></th><th align="left" valign="bottom"><bold>Group 1</bold><hr/></th><th align="left" valign="bottom"><bold>Group 2</bold><hr/></th><th align="left" valign="bottom"><bold>p value</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="left"><bold>(n&#x02009;=&#x02009;48)</bold></th><th align="left"><bold>(n&#x02009;=&#x02009;52)</bold></th><th align="left">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Age (year)<hr/></td><td align="left" valign="bottom">64.3&#x02009;&#x000b1;&#x02009;11.7<hr/></td><td align="left" valign="bottom">64.4&#x02009;&#x000b1;&#x02009;11.8<hr/></td><td align="left" valign="bottom">0.962<hr/></td></tr><tr><td align="left" valign="bottom">gender<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">0.029<hr/></td></tr><tr><td align="left" valign="bottom">Male<hr/></td><td align="left" valign="bottom">17(35.4%)<hr/></td><td align="left" valign="bottom">30(57.7%)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">female<hr/></td><td align="left" valign="bottom">31(65.6%)<hr/></td><td align="left" valign="bottom">22(42.3%)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">BMI (kg/m<sup>2</sup>)<hr/></td><td align="left" valign="bottom">21.9&#x02009;&#x000b1;&#x02009;3.3<hr/></td><td align="left" valign="bottom">22.7&#x02009;&#x000b1;&#x02009;3.3<hr/></td><td align="left" valign="bottom">0.248<hr/></td></tr><tr><td align="left" valign="bottom">KT/V<hr/></td><td align="left" valign="bottom">1.6&#x02009;&#x000b1;&#x02009;0.2<hr/></td><td align="left" valign="bottom">1.5&#x02009;&#x000b1;&#x02009;0.3<hr/></td><td align="left" valign="bottom">0.551<hr/></td></tr><tr><td align="left" valign="bottom">Dialysis vintage (m)<hr/></td><td align="left" valign="bottom">56.9&#x02009;&#x000b1;&#x02009;32.2<hr/></td><td align="left" valign="bottom">44.8&#x02009;&#x000b1;&#x02009;32.0<hr/></td><td align="left" valign="bottom">0.062<hr/></td></tr><tr><td align="left" valign="bottom">Diabetes<hr/></td><td align="left" valign="bottom">9/39(23.1%)<hr/></td><td align="left" valign="bottom">11/41(21.2%)<hr/></td><td align="left" valign="bottom">0.807<hr/></td></tr><tr><td align="left" valign="bottom">ACEI/ARB (case)<hr/></td><td align="left" valign="bottom">6/48(12.5%)<hr/></td><td align="left" valign="bottom">6/52(11.5%)<hr/></td><td align="left" valign="bottom">1.000<hr/></td></tr><tr><td align="left" valign="bottom">Statins (case)<hr/></td><td align="left" valign="bottom">2/48(4.2%)<hr/></td><td align="left" valign="bottom">3/52(5.8%)<hr/></td><td align="left" valign="bottom">1.000<hr/></td></tr><tr><td align="left" valign="bottom">BUN (mmol/l)<hr/></td><td align="left" valign="bottom">25.2&#x02009;&#x000b1;&#x02009;5.6<hr/></td><td align="left" valign="bottom">24.9&#x02009;&#x000b1;&#x02009;7.3<hr/></td><td align="left" valign="bottom">0.884<hr/></td></tr><tr><td align="left" valign="bottom">Scr (umol/l)<hr/></td><td align="left" valign="bottom">783.9&#x02009;&#x000b1;&#x02009;179.7<hr/></td><td align="left" valign="bottom">920.1&#x02009;&#x000b1;&#x02009;256.9<hr/></td><td align="left" valign="bottom">0.058<hr/></td></tr><tr><td align="left" valign="bottom">prealbumin (mg/l)<hr/></td><td align="left" valign="bottom">295.6&#x02009;&#x000b1;&#x02009;86.6<hr/></td><td align="left" valign="bottom">315.3&#x02009;&#x000b1;&#x02009;85.8<hr/></td><td align="left" valign="bottom">0.256<hr/></td></tr><tr><td align="left" valign="bottom">albumin (g/l)<hr/></td><td align="left" valign="bottom">38.2&#x02009;&#x000b1;&#x02009;3.7<hr/></td><td align="left" valign="bottom">40.0&#x02009;&#x000b1;&#x02009;4.2<hr/></td><td align="left" valign="bottom">0.023<hr/></td></tr><tr><td align="left" valign="bottom">hemoglobin (g/l)<hr/></td><td align="left" valign="bottom">107.2&#x02009;&#x000b1;&#x02009;16.6<hr/></td><td align="left" valign="bottom">111.4&#x02009;&#x000b1;&#x02009;17.3<hr/></td><td align="left" valign="bottom">0.217<hr/></td></tr><tr><td align="left" valign="bottom">ERI<hr/></td><td align="left" valign="bottom">10.7&#x02009;&#x000b1;&#x02009;8.6<hr/></td><td align="left" valign="bottom">9.3&#x02009;&#x000b1;&#x02009;6.1<hr/></td><td align="left" valign="bottom">0.323<hr/></td></tr><tr><td align="left" valign="bottom">Ferritin (ug/l)<hr/></td><td align="left" valign="bottom">417.8&#x02009;&#x000b1;&#x02009;266.5<hr/></td><td align="left" valign="bottom">461.9&#x02009;&#x000b1;&#x02009;287.1<hr/></td><td align="left" valign="bottom">0.429<hr/></td></tr><tr><td align="left" valign="bottom">Vitamin C (&#x003bc;g/mL)<hr/></td><td align="left" valign="bottom">1.5&#x02009;&#x000b1;&#x02009;0.8<hr/></td><td align="left" valign="bottom">2.0&#x02009;&#x000b1;&#x02009;0.9<hr/></td><td align="left" valign="bottom">0.003<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Median(IQR)<hr/></td><td align="left" valign="bottom">Median(IQR)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left">hsCRP(mg/l)</td><td align="left">9.6 (6.0-13.8)</td><td align="left">6.2(4.2-11.0)</td><td align="left">0.005</td></tr></tbody></table><table-wrap-foot><p>Note: age, BMI, dialysis vintage, BUN, Scr, prealbumin, albumin, hemoglobin, ERI and vitamin C were presented as mean&#x02009;&#x000b1;&#x02009;SD; hsCRP was presented as median and inter-quartile range (IQR).</p><p><italic>Abbreviations</italic>: <italic>BMI</italic> body mass index, <italic>BUN</italic> blood urea nitrogen, <italic>Scr</italic> serum creatinine, <italic>ERI</italic> EPO resistance index, <italic>hs-CRP</italic> high hypersensitive C-reactive protein, <italic>IQR</italic> inter quartile range.</p></table-wrap-foot></table-wrap><p>Among the 100 patients, the primary causes of ESRD were chronic glomerulonephritis (n&#x02009;=&#x02009;20), interstitial nephropathy (n&#x02009;=&#x02009;20), diabetic nephropathy (n&#x02009;=&#x02009;20), hypertensive nephrosclerosis (n&#x02009;=&#x02009;18), polycystic disease (n&#x02009;=&#x02009;11), chronic pyelonephritis (n&#x02009;=&#x02009;3) and others (n&#x02009;=&#x02009;8). Table&#x000a0;<xref ref-type="table" rid="T1">1</xref> lists the detailed demographics.</p><p>Patients in group 2 exhibited lower hs-CRP level, higher vitamin C and albumin levels compared with group 1. Moreover, there were more males in group 2. No statistical significance was found in terms of age, gender, body mass index, dialysis vintage, Kt/V, prealbumin, hemoglobin and ERI between two groups.</p></sec><sec><title>Change of vitamin C level during the study</title><p>At the baseline, the plasma vitamin C level of all patients was less than 4&#x000a0;&#x003bc;g/mL. However, this proportion was decreased to 20% after the vitamin C supplementation for 3&#x000a0;months.</p><p>For group 1, the vitamin C level was significantly increased at the end of the first 3&#x000a0;months (p&#x02009;&#x0003c;&#x02009;0.001) compared with that at the baseline. After the vitamin C supplementation was withdrawn, the vitamin C level was significantly decreased at the end of the second 3&#x000a0;months compared with that at the end of the first 3&#x000a0;months (p&#x02009;&#x0003c;&#x02009;0.001). Moreover, no significant difference in the vitamin C level was found between the end of the second 3&#x000a0;months and the baseline (p&#x02009;=&#x02009;0.606) (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Influence of vitamin C supplementation on plasma vitamin C level.</bold> group1: patients were given oral vitamin C 200&#x000a0;mg per day during the first 3&#x000a0;months and withdraw vitamin C thereafter. group2: patients were given vitamin C during the second 3&#x000a0;months; vitamin C was presented as mean&#x02009;&#x000b1;&#x02009;SD; levels of vitamin C were compared among groups using one-way analysis of variance (1-way-ANOVA).</p></caption><graphic xlink:href="1471-2369-14-252-1"/></fig><p>For group 2, the vitamin C level remained unchanged at the end of the first 3&#x000a0;months (p&#x02009;=&#x02009;0.837) compared with that at the baseline. However, it was significantly increased at the end of the second 3&#x000a0;months compared with that at the baseline (p&#x02009;&#x0003c;&#x02009;0.001) and the end of the first 3&#x000a0;months (p&#x02009;&#x0003c;&#x02009;0.001) (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>).</p></sec><sec><title>Change of hs-CRP level during the study</title><p>For group 1, the hs-CRP level was significantly decreased at the end of the first 3&#x000a0;months (p&#x02009;&#x0003c;&#x02009;0.001) compared with that at the baseline. After the vitamin C supplementation was withdrawn, the hs-CRP level was significantly increased at the end of the second 3&#x000a0;months compared with that at the end of the first 3&#x000a0;months (p&#x02009;=&#x02009;0.014). Moreover, no significant difference in the hs-CRP level was found between the end of the second 3&#x000a0;months and the baseline (p&#x02009;=&#x02009;0.106) (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Effect of vitamin C supplementation on plasma hs-CRP level.</bold> Group 1: patients were orally administered with 200&#x000a0;mg/day vitamin C during the first 3&#x000a0;months, and the vitamin C administration was withdrawn thereafter. Group 2: patients were administered with vitamin C during the second 3&#x000a0;months. Hs-CRP level was presented as Median (IQR); levels of hs-CRP were compared among groups using Kruskal Wallis Test.</p></caption><graphic xlink:href="1471-2369-14-252-2"/></fig><p>For group 2, the hs-CRP level remained unchanged at the end of the first 3&#x000a0;months (p&#x02009;=&#x02009;0.663) compared with that at the baseline. However, it was significantly decreased at the end of the second 3&#x000a0;months compared with that at the baseline (p&#x02009;=&#x02009;0.005) and the end of the first 3&#x000a0;months (p&#x02009;&#x0003c;&#x02009;0.001) (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>).</p></sec><sec><title>Change of prealbumin and albumin levels during the study</title><p>For group 1, levels of prealbumin and albumin exhibited a slight increase (p&#x02009;&#x0003e;&#x02009;0.05) at the end of the first 3&#x000a0;months compared with those at the baseline. After the vitamin C supplementation was withdrawn, levels of prealbumin and albumin (p&#x02009;&#x0003e;&#x02009;0.05) were decreased at the end of the second 3&#x000a0;months (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Effect of vitamin C supplementation on parameters during 6&#x000a0;months (n&#x02009;=&#x02009;100)</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom"><bold>Item</bold><hr/></th><th colspan="3" align="left" valign="bottom"><bold>Group 1 (n&#x02009;=&#x02009;48)</bold><hr/></th><th colspan="3" align="left" valign="bottom"><bold>Group 2 (n&#x02009;=&#x02009;52)</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="left"><bold>Baseline</bold></th><th align="left"><bold>Month 3</bold></th><th align="left"><bold>Month 6</bold></th><th align="left"><bold>Baseline</bold></th><th align="left"><bold>Month 3</bold></th><th align="left"><bold>Month 6</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">prealbumin (mg/l)<hr/></td><td align="left" valign="bottom">295.6&#x02009;&#x000b1;&#x02009;86.6<hr/></td><td align="left" valign="bottom">296.7&#x02009;&#x000b1;&#x02009;60.1<hr/></td><td align="left" valign="bottom">272.1&#x02009;&#x000b1;&#x02009;69.3<hr/></td><td align="left" valign="bottom">315.3&#x02009;&#x000b1;&#x02009;85.8<hr/></td><td align="left" valign="bottom">302.9&#x02009;&#x000b1;&#x02009;60.3<hr/></td><td align="left" valign="bottom">336.9&#x02009;&#x000b1;&#x02009;69.5<sup>a</sup><hr/></td></tr><tr><td align="left" valign="bottom">albumin (g/l)<hr/></td><td align="left" valign="bottom">38.2&#x02009;&#x000b1;&#x02009;3.7<hr/></td><td align="left" valign="bottom">38.3&#x02009;&#x000b1;&#x02009;3.1<hr/></td><td align="left" valign="bottom">37.6&#x02009;&#x000b1;&#x02009;2.6<hr/></td><td align="left" valign="bottom">40.0&#x02009;&#x000b1;&#x02009;4.2<hr/></td><td align="left" valign="bottom">39.6&#x02009;&#x000b1;&#x02009;2.8<hr/></td><td align="left" valign="bottom">40.4&#x02009;&#x000b1;&#x02009;2.4<hr/></td></tr><tr><td align="left" valign="bottom">hemoglobin (g/l)<hr/></td><td align="left" valign="bottom">107.2&#x02009;&#x000b1;&#x02009;16.6<hr/></td><td align="left" valign="bottom">109.9&#x02009;&#x000b1;&#x02009;14.1<hr/></td><td align="left" valign="bottom">109.3&#x02009;&#x000b1;&#x02009;14.2<hr/></td><td align="left" valign="bottom">111.4&#x02009;&#x000b1;&#x02009;17.3<hr/></td><td align="left" valign="bottom">110.9&#x02009;&#x000b1;&#x02009;20.4<hr/></td><td align="left" valign="bottom">111.9&#x02009;&#x000b1;&#x02009;25.4<hr/></td></tr><tr><td align="left" valign="bottom">ERI<hr/></td><td align="left" valign="bottom">10.7&#x02009;&#x000b1;&#x02009;8.6<hr/></td><td align="left" valign="bottom">8.3&#x02009;&#x000b1;&#x02009;6.6<hr/></td><td align="left" valign="bottom">9.1&#x02009;&#x000b1;&#x02009;7.4<hr/></td><td align="left" valign="bottom">9.3&#x02009;&#x000b1;&#x02009;6.1<hr/></td><td align="left" valign="bottom">8.6&#x02009;&#x000b1;&#x02009;6.7<hr/></td><td align="left" valign="bottom">7.5&#x02009;&#x000b1;&#x02009;6.4<hr/></td></tr><tr><td align="left" valign="bottom">Ferritin (ug/l)<hr/></td><td align="left" valign="bottom">417.8&#x02009;&#x000b1;&#x02009;266.5<hr/></td><td align="left" valign="bottom">355.0&#x02009;&#x000b1;&#x02009;256.4<hr/></td><td align="left" valign="bottom">444.2&#x02009;&#x000b1;&#x02009;333.5<hr/></td><td align="left" valign="bottom">461.9&#x02009;&#x000b1;&#x02009;287.1<hr/></td><td align="left" valign="bottom">500.0&#x02009;&#x000b1;&#x02009;314.2<hr/></td><td align="left" valign="bottom">445.9&#x02009;&#x000b1;&#x02009;352.7<hr/></td></tr><tr><td align="left" valign="bottom">Vitamin C (&#x003bc;g/mL)<hr/></td><td align="left" valign="bottom">1.5&#x02009;&#x000b1;&#x02009;0.8<hr/></td><td align="left" valign="bottom">10.4&#x02009;&#x000b1;&#x02009;10.3<sup>b</sup><hr/></td><td align="left" valign="bottom">2.1&#x02009;&#x000b1;&#x02009;1.6<sup>c</sup><hr/></td><td align="left" valign="bottom">2.0&#x02009;&#x000b1;&#x02009;0.9<hr/></td><td align="left" valign="bottom">2.1&#x02009;&#x000b1;&#x02009;1.3<hr/></td><td align="left" valign="bottom">9.1&#x02009;&#x000b1;&#x02009;4.3<sup>bc</sup><hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Median(IQR)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Median(IQR)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">rHuEpo (x10<sup>3</sup>U/week)<hr/></td><td align="left" valign="bottom">6.0(3.0-9.0)<hr/></td><td align="left" valign="bottom">4.5(2.8-6.0)<hr/></td><td align="left" valign="bottom">5.2(2.6-8.8)<hr/></td><td align="left" valign="bottom">6.0(4.0-8.8)<hr/></td><td align="left" valign="bottom">6.0(3.0-8.8)<hr/></td><td align="left" valign="bottom">4.2(2.7-6.0)<hr/></td></tr><tr><td align="left">hsCRP (mg/l)</td><td align="left">9.6 (6.0-13.8)</td><td align="left">4.9(3.7-8.7)<sup>b</sup></td><td align="left">8.1(5.1-11.3)<sup>d</sup></td><td align="left">6.2(4.2-11.0)</td><td align="left">7.1(5.2-8.8)</td><td align="left">5.1(2.6-6.5)<sup>bc</sup></td></tr></tbody></table><table-wrap-foot><p>Note: <sup>a</sup>p&#x02009;&#x0003c;&#x02009;0.05:compared with group baseline; <sup>b</sup>p&#x02009;&#x0003c;&#x02009;0.01:compared with group baseline; <sup>c</sup>p&#x02009;&#x0003c;&#x02009;0.01:compared with group Month 3; <sup>d</sup>p&#x02009;&#x0003c;&#x02009;0.05:compared with group Month 3; prealbumin, albumin, hemoglobin, ERI, ferritin and vitamin C levels were presented as mean&#x02009;&#x000b1;&#x02009;SD; EPO dosage and hs-CRP level were presented as median and inter-quartile range (IQR).</p><p><italic>Abbreviations</italic>: <italic>ERI</italic> EPO resistance index, <italic>rHuEpo</italic>, recombinant human erythropoietin, <italic>hs-CRP</italic> high hypersensitive C-reactive protein, <italic>IQR</italic> inter quartile range.</p></table-wrap-foot></table-wrap><p>For group 2, levels of prealbumin and albumin remained unchanged at the end of the first 3&#x000a0;months (p&#x02009;&#x0003e;&#x02009;0.05) compared with those at the baseline. However, a significant increase in prealbumin (p&#x02009;=&#x02009;0.018) and an increase trend in albumin (p&#x02009;&#x0003e;&#x02009;0.05) were observed at the end of the second 3&#x000a0;months compared with those at the end of the first 3&#x000a0;months (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p></sec><sec><title>Change of ERI during the study</title><p>For group 1, a decrease trend in ERI, ferritin and EPO dosage (all p&#x02009;&#x0003e;&#x02009;0.05) and an increase trend in hemoglobin (p&#x02009;&#x0003e;&#x02009;0.05) were observed at the end of the first 3&#x000a0;months compared with those at the baseline. At the end of the second 3&#x000a0;months, ERI, ferritin and EPO dosage (all p&#x02009;&#x0003e;&#x02009;0.05) were increased without statistical significance compared with those at the end of the first 3&#x000a0;months, whereas the hemoglobin level remained unchanged at the end of the second 3&#x000a0;months (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p><p>For group 2, a decrease trend in ERI and hemoglobin and an increase trend in ferritin were observed at the end of the first 3&#x000a0;months compared with those at the baseline (all p&#x02009;&#x0003e;&#x02009;0.05), whereas the EPO dosage remained unchanged. At the end of the second 3&#x000a0;months, a decrease trend in ERI, ferritin and EPO dosage and an increase trend in hemoglobin were observed (all p&#x02009;&#x0003e;&#x02009;0.05) compared with those at the end of the first 3&#x000a0;months (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In the present study, we showed that the plasma hs-CRP level in MHD patients could be reduced by oral vitamin C supplementation. The proportion of patients with a plasma vitamin C level of less than 4&#x000a0;&#x003bc;g/mL was decreased to 20% after the vitamin C supplementation for 3&#x000a0;months. We also found an increase trend in plasma prealbumin level after the vitamin C supplementation. In addition, a better plasma albumin, hemoglobin, EPO dosage and ERI response to vitamin C supplementation was observed without statistical significance.</p><p>Previous study demonstrated that MHD patients have remarkably low plasma vitamin C levels, frequently&#x02009;&#x0003c;&#x02009;10&#x000a0;&#x003bc;M, even&#x02009;&#x0003c;&#x02009;2&#x000a0;&#x003bc;M [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. In our previous study, a plasma vitamin C level of&#x02009;&#x0003c;&#x02009;4&#x000a0;&#x003bc;g/mL (22.8&#x000a0;&#x003bc;mol/L) is presented in 64.4% dialysis patients [<xref ref-type="bibr" rid="B12">12</xref>]. In our current study, 20% patients still exhibited a persistent low plasma vitamin C level after the vitamin C supplementation for 3&#x000a0;months, suggesting that an individualized dosage of vitamin C supplementation should be considered.</p><p>Low-level, persistent inflammation is prevalent in MHD patients, although there is no convincing evidence of systemic or restricted infection in clinical practice. Vitamin C deficiency is caused by inadequate dietary intake, loss during dialysis procedure, impaired metabolism and reduced tubular reabsorption [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>].</p><p>Miyata and Wang S. et al. observed that the concentration of <italic>in vitro</italic> plasma ascorbic acid in uremic patients is decreased more rapidly (0.16% per min) than that in normal subjects (0.09% per min) [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. This finding suggested that the uremic plasma consumes more vitamin C than healthy plasma, which may be related to excessive toxin retention and metabolic acidosis [<xref ref-type="bibr" rid="B25">25</xref>]. <italic>In vivo</italic>, the volume overload [<xref ref-type="bibr" rid="B26">26</xref>] and bio-incompatibility of dialysis materials and non-sterile dialysate may also contribute to the inflammatory status [<xref ref-type="bibr" rid="B27">27</xref>].</p><p>In our previous cross-sectional study, we found that a negative correlation existed between the plasma vitamin C level and inflammation status in MHD patients [<xref ref-type="bibr" rid="B12">12</xref>]. We hypothesized that vitamin C, as an electron donor, had anti-oxidative effects, and its oral supplementation could improve the inflammatory status in MHD patients. Tarng D C et al. [<xref ref-type="bibr" rid="B28">28</xref>] reported that the 8-OHdG level of cellular DNA, as an evaluative indicator of oxidative DNA damage in reactive oxygen species-mediated diseases [<xref ref-type="bibr" rid="B15">15</xref>], is reduced after the vitamin C supplementation for 8&#x000a0;weeks in chronic hemodialysis patients. However, this beneficial effect in MHD patients has not been reported by other studies. In Fumeron&#x02019;s study [<xref ref-type="bibr" rid="B13">13</xref>], 33 MHD patients were orally administered with 250&#x000a0;mg vitamin C thrice weekly after each dialysis session for 2&#x000a0;months, and no evident improvement is observed in oxidative/anti-oxidative stress and inflammation markers. Kamgar M et al. [<xref ref-type="bibr" rid="B14">14</xref>] reported a decrease trend in CRP level after an oral supplementation of 250&#x000a0;mg/day vitamin C for 2&#x000a0;months in 20 MHD patients. In our present study, the hs-CRP level was decreased by oral supplementation of 200&#x000a0;mg/day vitamin C in both groups, and the hs-CRP level was increased again after the vitamin C supplementation was withdrawn in group 1. Unlike other inconclusive results from previous studies, we showed that the vitamin C supplementation doubtlessly had a beneficial effect. Our results were more convincing due to following advantages: (1) relative larger sample size; (2) relative longer period of observation; (3) randomized controlled cross-over design; (4) more importantly, selected patients were with low vitamin C level and high hs-CRP level, and this patient population might respond well to inflammation-induced vitamin C consumption. In this study, several patients took anti-inflammatory drugs, such as ACEI/ARB, statins, but remain unchanged during the study period. Therefore, the anti-inflammatory effects of these drugs on our patients could be sagely ignored.</p><p>Recent evidence showed that the plasma vitamin C level is positively associated with levels of hemoglobin [<xref ref-type="bibr" rid="B29">29</xref>], albumin [<xref ref-type="bibr" rid="B30">30</xref>] and prealbumin [<xref ref-type="bibr" rid="B12">12</xref>], and negatively associated with ERI [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B33">33</xref>]. After 6&#x000a0;months of vitamin C supplementation, levels of prealbumin, albumin and hemoglobin are significantly increased in the preliminary study. In the present randomized controlled cross-over study, we also found beneficial responses of these markers upon the vitamin C supplementation, but statistically insignificant, which could be due to the long half-life of serum albumin and hemoglobin, and the short interventional duration. These beneficial effects might be caused by anti-oxidative effect of vitamin C.</p><p>Consistent with our data, previous study showed that the vitamin C supplementation improves the responsiveness to EPO in hemodialysis patients with refractory anemia and hyperferritinemia [<xref ref-type="bibr" rid="B31">31</xref>]. In our present study, a decrease trend in ERI, ferritin and EPO dosage, and an increase trend in hemoglobin were observed after the oral vitamin C supplementation for 3&#x000a0;months. One possible mechanism for this effect might be the electron offering ability of vitamin C. Vitamin C mobilizes storage iron by reducing ferric iron (Fe<sup>+3</sup>) to ferrous iron (Fe<sup>+2</sup>), including the portion of tissue iron as hemosiderin [<xref ref-type="bibr" rid="B34">34</xref>], leading to an increased bioavailability of iron and improved red blood cell production. In the present study, the improvement in hemoglobin was associated with significantly decreased hs-CRP levels during the vitamin C supplementation, but not in controls, which might be due to the anti-oxidative ability of vitamin C.</p><p>In this study, the prealbumin concentration was significantly increased after the oral vitamin C administration in group 2 but not in group 1, and ERI was decreased in group 2 even in without-drug phase. Therefore, some other important factors, in addition to the relatively short interventional duration, were probably not included in the present investigation.</p><p>In order to minimize the possible accumulation of oxalate in patients, the dosage of vitamin C was selected as 200&#x000a0;mg/day. Dosages as high as 500 to 1,000&#x000a0;mg/day for 3 or more than 3&#x000a0;weeks induce significantly increased plasma oxalate levels [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Our present study had some limitations as follows. (1) The duration of the intervention was relatively short, although changes in hs-CRP level were observed. Changes of albumin, prealbumin, hemoglobin, EPO dosages and ERI were not significant due to their relatively longer half-life, because duration of 3&#x000a0;months only permitted one red blood cell life-span to reach steady state [<xref ref-type="bibr" rid="B37">37</xref>]. (2) A total of 28 (21.9%) patients dropped out during the observation, which might result in the imbalance of parameters between the two groups. (3) This investigation did not contain the placebo in the control group.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In conclusion, our cross-over study indicated that the inflammatory status in MHD patients with plasma vitamin C deficiency and high levels of inflammatory markers could be partially improved by long-term oral administration of small doses of vitamin C. A multi-center randomized controlled study with relatively larger sample size is required to confirm the role of vitamin C in improving the micro-inflammatory state in MHD patients. Moreover, further study is also necessary to assess the long-term outcome of oral vitamin C supplementation in MHD patients.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>ZKY participated in the design of the study, sampling procedure, and drafted the manuscript. LYH, CXY, LL, BWY, GWY and WLY participated in the design of the study and sampling procedure. ZL conceived the study, and participated in its design and coordination and performed statistical analysis. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2369/14/252/prepub">http://www.biomedcentral.com/1471-2369/14/252/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>The authors are grateful to Professor Geng Qiuming, Central Lab, Peking University Third Hospital, for sampling procedure and statistical advice.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Foley</surname><given-names>RN</given-names></name><name><surname>Parfrey</surname><given-names>PS</given-names></name><name><surname>Sarnak</surname><given-names>MJ</given-names></name><article-title>Clinical epidemiology of cardiovascular disease in chronic renal disease</article-title><source>Am J Kidney Dis</source><year>1998</year><volume>32</volume><issue>5 Suppl 3</issue><fpage>S112</fpage><lpage>S119</lpage><pub-id pub-id-type="pmid">9820470</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Yeun</surname><given-names>JY</given-names></name><name><surname>Levine</surname><given-names>RA</given-names></name><name><surname>Mantadilok</surname><given-names>V</given-names></name><name><surname>Kaysen</surname><given-names>GA</given-names></name><article-title>C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>2000</year><volume>35</volume><issue>3</issue><fpage>469</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(00)70200-9</pub-id><pub-id pub-id-type="pmid">10692273</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Zoccali</surname><given-names>C</given-names></name><article-title>Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors?</article-title><source>Nephrol Dial Transplant</source><year>2000</year><volume>15</volume><issue>4</issue><fpage>454</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1093/ndt/15.4.454</pub-id><pub-id pub-id-type="pmid">10727537</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Owen</surname><given-names>WF</given-names></name><name><surname>Lowrie</surname><given-names>EG</given-names></name><article-title>C-reactive protein as an outcome predictor for maintenance hemodialysis patients</article-title><source>Kidney Int</source><year>1998</year><volume>54</volume><issue>2</issue><fpage>627</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.1998.00032.x</pub-id><pub-id pub-id-type="pmid">9690231</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><article-title>Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men</article-title><source>N Engl J Med</source><year>1997</year><volume>336</volume><issue>14</issue><fpage>973</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1056/NEJM199704033361401</pub-id><pub-id pub-id-type="pmid">9077376</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Zimmermann</surname><given-names>J</given-names></name><name><surname>Herrlinger</surname><given-names>S</given-names></name><name><surname>Pruy</surname><given-names>A</given-names></name><name><surname>Metzger</surname><given-names>T</given-names></name><name><surname>Wanner</surname><given-names>C</given-names></name><article-title>Inflammation enhances cardiovascular risk and mortality in hemodialysis patients</article-title><source>Kidney Int</source><year>1999</year><volume>55</volume><issue>2</issue><fpage>648</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.1999.00273.x</pub-id><pub-id pub-id-type="pmid">9987089</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Morena</surname><given-names>M</given-names></name><name><surname>Cristol</surname><given-names>JP</given-names></name><name><surname>Bosc</surname><given-names>JY</given-names></name><name><surname>Tetta</surname><given-names>C</given-names></name><name><surname>Forret</surname><given-names>G</given-names></name><name><surname>Leger</surname><given-names>CL</given-names></name><name><surname>Delcourt</surname><given-names>C</given-names></name><name><surname>Papoz</surname><given-names>L</given-names></name><name><surname>Descomps</surname><given-names>B</given-names></name><name><surname>Canaud</surname><given-names>B</given-names></name><article-title>Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2002</year><volume>17</volume><issue>3</issue><fpage>422</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1093/ndt/17.3.422</pub-id><pub-id pub-id-type="pmid">11865087</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Eide</surname><given-names>TC</given-names></name><name><surname>Sogn</surname><given-names>EM</given-names></name><name><surname>Berg</surname><given-names>KJ</given-names></name><name><surname>Sund</surname><given-names>RB</given-names></name><article-title>Plasma ascorbic acid in patients undergoing chronic haemodialysis</article-title><source>Eur J Clin Pharmacol</source><year>1999</year><volume>55</volume><issue>7</issue><fpage>527</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1007/s002280050668</pub-id><pub-id pub-id-type="pmid">10501823</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Washio</surname><given-names>K</given-names></name><name><surname>Inagaki</surname><given-names>M</given-names></name><name><surname>Tsuji</surname><given-names>M</given-names></name><name><surname>Morio</surname><given-names>Y</given-names></name><name><surname>Akiyama</surname><given-names>S</given-names></name><name><surname>Gotoh</surname><given-names>H</given-names></name><name><surname>Gotoh</surname><given-names>T</given-names></name><name><surname>Gotoh</surname><given-names>Y</given-names></name><name><surname>Oguchi</surname><given-names>K</given-names></name><article-title>Oral vitamin C supplementation in hemodialysis patients and its effect on the plasma level of oxidized ascorbic acid and Cu/Zn superoxide dismutase, an oxidative stress marker</article-title><source>Nephron Clin Pract</source><year>2008</year><volume>109</volume><issue>2</issue><fpage>c49</fpage><lpage>c54</lpage><pub-id pub-id-type="doi">10.1159/000137628</pub-id><pub-id pub-id-type="pmid">18544955</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Sullivan</surname><given-names>JF</given-names></name><name><surname>Eisenstein</surname><given-names>AB</given-names></name><article-title>Ascorbic acid depletion during hemodialysis</article-title><source>JAMA</source><year>1972</year><volume>220</volume><issue>13</issue><fpage>1697</fpage><lpage>1699</lpage><pub-id pub-id-type="doi">10.1001/jama.1972.03200130029006</pub-id><pub-id pub-id-type="pmid">5067604</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Paniagua</surname><given-names>R</given-names></name><name><surname>Frias</surname><given-names>Y</given-names></name><name><surname>de Ventura</surname><given-names>MJ</given-names></name><name><surname>Rodriguez</surname><given-names>E</given-names></name><name><surname>Hurtado</surname><given-names>ME</given-names></name><name><surname>Alcantara</surname><given-names>G</given-names></name><name><surname>Vazquez</surname><given-names>R</given-names></name><name><surname>Ortiz</surname><given-names>R</given-names></name><name><surname>Salcedo</surname><given-names>M</given-names></name><name><surname>Rios</surname><given-names>ME</given-names></name><etal/><article-title>C-reactive protein and anti-Chlamydia pneumoniae antibodies as risk factors of cardiovascular death in incident patients on peritoneal dialysis</article-title><source>Perit Dial Int</source><year>2003</year><volume>23</volume><issue>2</issue><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">12713079</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Geng</surname><given-names>Q</given-names></name><name><surname>Zuo</surname><given-names>L</given-names></name><article-title>Low levels of vitamin C in dialysis patients is associated with decreased prealbumin and increased C-reactive protein</article-title><source>BMC Nephrol</source><year>2011</year><volume>12</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/1471-2369-12-18</pub-id><pub-id pub-id-type="pmid">21548917</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Fumeron</surname><given-names>C</given-names></name><name><surname>Nguyen-Khoa</surname><given-names>T</given-names></name><name><surname>Saltiel</surname><given-names>C</given-names></name><name><surname>Kebede</surname><given-names>M</given-names></name><name><surname>Buisson</surname><given-names>C</given-names></name><name><surname>Drueke</surname><given-names>TB</given-names></name><name><surname>Lacour</surname><given-names>B</given-names></name><name><surname>Massy</surname><given-names>ZA</given-names></name><article-title>Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2005</year><volume>20</volume><issue>9</issue><fpage>1874</fpage><lpage>1879</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfh928</pub-id><pub-id pub-id-type="pmid">15972322</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Kamgar</surname><given-names>M</given-names></name><name><surname>Zaldivar</surname><given-names>F</given-names></name><name><surname>Vaziri</surname><given-names>ND</given-names></name><name><surname>Pahl</surname><given-names>MV</given-names></name><article-title>Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease</article-title><source>J Natl Med Assoc</source><year>2009</year><volume>101</volume><issue>4</issue><fpage>336</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">19397224</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Kasai</surname><given-names>H</given-names></name><article-title>Analysis of a form of oxidative DNA damage, 8-hydroxy-2&#x02032;-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis</article-title><source>Mutat Res</source><year>1997</year><volume>387</volume><issue>3</issue></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zuo</surname><given-names>L</given-names></name><article-title>Association between vitamin C deficiency and dialysis modalities</article-title><source>Nephrology (Carlton)</source><year>2012</year><volume>17</volume><issue>5</issue><fpage>452</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1797.2012.01595.x</pub-id><pub-id pub-id-type="pmid">22404236</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Reuler</surname><given-names>JB</given-names></name><name><surname>Broudy</surname><given-names>VC</given-names></name><name><surname>Cooney</surname><given-names>TG</given-names></name><article-title>Adult scurvy</article-title><source>JAMA</source><year>1985</year><volume>253</volume><issue>6</issue><fpage>805</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1001/jama.1985.03350300093027</pub-id><pub-id pub-id-type="pmid">3968818</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Richter</surname><given-names>A</given-names></name><name><surname>Kuhlmann</surname><given-names>MK</given-names></name><name><surname>Seibert</surname><given-names>E</given-names></name><name><surname>Kotanko</surname><given-names>P</given-names></name><name><surname>Levin</surname><given-names>NW</given-names></name><name><surname>Handelman</surname><given-names>GJ</given-names></name><article-title>Vitamin C deficiency and secondary hyperparathyroidism in chronic haemodialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2008</year><volume>23</volume><issue>6</issue><fpage>2058</fpage><lpage>2063</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfn084</pub-id><pub-id pub-id-type="pmid">18353890</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>P</given-names></name><name><surname>Loughrey</surname><given-names>CM</given-names></name><name><surname>Lightbody</surname><given-names>JH</given-names></name><name><surname>McNamee</surname><given-names>PT</given-names></name><name><surname>Young</surname><given-names>IS</given-names></name><article-title>Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure</article-title><source>Clin Chem</source><year>1995</year><volume>41</volume><issue>8 Pt 1</issue><fpage>1135</fpage><lpage>1138</lpage><pub-id pub-id-type="pmid">7628087</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Alkhunaizi</surname><given-names>AM</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name><article-title>Secondary oxalosis: a cause of delayed recovery of renal function in the setting of acute renal failure</article-title><source>J Am Soc Nephrol</source><year>1996</year><volume>7</volume><issue>11</issue><fpage>2320</fpage><lpage>2326</lpage><pub-id pub-id-type="pmid">8959621</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Durose</surname><given-names>CL</given-names></name><name><surname>Holdsworth</surname><given-names>M</given-names></name><name><surname>Watson</surname><given-names>V</given-names></name><name><surname>Przygrodzka</surname><given-names>F</given-names></name><article-title>Knowledge of dietary restrictions and the medical consequences of noncompliance by patients on hemodialysis are not predictive of dietary compliance</article-title><source>J Am Diet Assoc</source><year>2004</year><volume>104</volume><issue>1</issue><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.jada.2003.10.016</pub-id><pub-id pub-id-type="pmid">14702581</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Boeschoten</surname><given-names>EW</given-names></name><name><surname>Schrijver</surname><given-names>J</given-names></name><name><surname>Krediet</surname><given-names>RT</given-names></name><name><surname>Schreurs</surname><given-names>WH</given-names></name><name><surname>Arisz</surname><given-names>L</given-names></name><article-title>Deficiencies of vitamins in CAPD patients: the effect of supplementation</article-title><source>Nephrol Dial Transplant</source><year>1988</year><volume>3</volume><issue>2</issue><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">3140085</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Schram</surname><given-names>IM</given-names></name><name><surname>Sund</surname><given-names>RB</given-names></name><article-title>Determination of plasma ascorbic acid by HPLC: method and stability studies</article-title><source>Eur J Pharm Sci</source><year>1995</year><volume>3</volume><issue>4</issue><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/0928-0987(95)00011-2</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Miyata</surname><given-names>T</given-names></name><name><surname>Wada</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Iida</surname><given-names>Y</given-names></name><name><surname>Horie</surname><given-names>K</given-names></name><name><surname>Yasuda</surname><given-names>Y</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Kurokawa</surname><given-names>K</given-names></name><name><surname>van Ypersele</surname><given-names>DSC</given-names></name><article-title>Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure</article-title><source>Kidney Int</source><year>1997</year><volume>51</volume><issue>4</issue><fpage>1170</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1038/ki.1997.160</pub-id><pub-id pub-id-type="pmid">9083283</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Bellocq</surname><given-names>A</given-names></name><name><surname>Suberville</surname><given-names>S</given-names></name><name><surname>Philippe</surname><given-names>C</given-names></name><name><surname>Bertrand</surname><given-names>F</given-names></name><name><surname>Perez</surname><given-names>J</given-names></name><name><surname>Fouqueray</surname><given-names>B</given-names></name><name><surname>Cherqui</surname><given-names>G</given-names></name><name><surname>Baud</surname><given-names>L</given-names></name><article-title>Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages. Evidence for involvement of nuclear factor-kappaB activation</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><issue>9</issue><fpage>5086</fpage><lpage>5092</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.9.5086</pub-id><pub-id pub-id-type="pmid">9478960</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Demirci</surname><given-names>MS</given-names></name><name><surname>Demirci</surname><given-names>C</given-names></name><name><surname>Ozdogan</surname><given-names>O</given-names></name><name><surname>Kircelli</surname><given-names>F</given-names></name><name><surname>Akcicek</surname><given-names>F</given-names></name><name><surname>Basci</surname><given-names>A</given-names></name><name><surname>Ok</surname><given-names>E</given-names></name><name><surname>Ozkahya</surname><given-names>M</given-names></name><article-title>Relations between malnutrition-inflammation-atherosclerosis and volume status. The usefulness of bioimpedance analysis in peritoneal dialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2011</year><volume>26</volume><issue>5</issue><fpage>1708</fpage><lpage>1716</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfq588</pub-id><pub-id pub-id-type="pmid">20921295</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Stenvinkel</surname><given-names>P</given-names></name><name><surname>Alvestrand</surname><given-names>A</given-names></name><article-title>Inflammation in end-stage renal disease: sources, consequences, and therapy</article-title><source>Semin Dial</source><year>2002</year><volume>15</volume><issue>5</issue><fpage>329</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1046/j.1525-139X.2002.00083.x</pub-id><pub-id pub-id-type="pmid">12358637</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Tarng</surname><given-names>DC</given-names></name><name><surname>Liu</surname><given-names>TY</given-names></name><name><surname>Huang</surname><given-names>TP</given-names></name><article-title>Protective effect of vitamin C on 8-hydroxy-2&#x02032;-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients</article-title><source>Kidney Int</source><year>2004</year><volume>66</volume><issue>2</issue><fpage>820</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00809.x</pub-id><pub-id pub-id-type="pmid">15253739</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Finkelstein</surname><given-names>FO</given-names></name><name><surname>Juergensen</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Santacroce</surname><given-names>S</given-names></name><name><surname>Levine</surname><given-names>M</given-names></name><name><surname>Kotanko</surname><given-names>P</given-names></name><name><surname>Levin</surname><given-names>NW</given-names></name><name><surname>Handelman</surname><given-names>GJ</given-names></name><article-title>Hemoglobin and plasma vitamin C levels in patients on peritoneal dialysis</article-title><source>Perit Dial Int</source><year>2011</year><volume>31</volume><issue>1</issue><fpage>74</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.3747/pdi.2009.00154</pub-id><pub-id pub-id-type="pmid">20558814</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Myint</surname><given-names>CC</given-names></name><name><surname>Tay</surname><given-names>ME</given-names></name><name><surname>Yusuf</surname><given-names>N</given-names></name><name><surname>Ong</surname><given-names>CN</given-names></name><article-title>Serum ascorbic acid and protein calorie malnutrition in continuous ambulatory peritoneal dialysis patients</article-title><source>Adv Perit Dial</source><year>2001</year><volume>17</volume><fpage>219</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">11510280</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Attallah</surname><given-names>N</given-names></name><name><surname>Osman-Malik</surname><given-names>Y</given-names></name><name><surname>Frinak</surname><given-names>S</given-names></name><name><surname>Besarab</surname><given-names>A</given-names></name><article-title>Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia</article-title><source>Am J Kidney Dis</source><year>2006</year><volume>47</volume><issue>4</issue><fpage>644</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2005.12.025</pub-id><pub-id pub-id-type="pmid">16564942</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Deicher</surname><given-names>R</given-names></name><name><surname>Ziai</surname><given-names>F</given-names></name><name><surname>Habicht</surname><given-names>A</given-names></name><name><surname>Bieglmayer</surname><given-names>C</given-names></name><name><surname>Schillinger</surname><given-names>M</given-names></name><name><surname>Horl</surname><given-names>WH</given-names></name><article-title>Vitamin C plasma level and response to erythropoietin in patients on maintenance haemodialysis</article-title><source>Nephrol Dial Transplant</source><year>2004</year><volume>19</volume><issue>9</issue><fpage>2319</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfh260</pub-id><pub-id pub-id-type="pmid">15299098</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Keven</surname><given-names>K</given-names></name><name><surname>Kutlay</surname><given-names>S</given-names></name><name><surname>Nergizoglu</surname><given-names>G</given-names></name><name><surname>Erturk</surname><given-names>S</given-names></name><article-title>Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>2003</year><volume>41</volume><issue>6</issue><fpage>1233</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(03)00356-1</pub-id><pub-id pub-id-type="pmid">12776276</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>CH</given-names></name><name><surname>Bidlack</surname><given-names>WR</given-names></name><article-title>Interrelationship of dietary ascorbic acid and iron on the tissue distribution of ascorbic acid, iron and copper in female guinea pigs</article-title><source>J Nutr</source><year>1980</year><volume>110</volume><issue>7</issue><fpage>1398</fpage><lpage>1408</lpage><pub-id pub-id-type="pmid">7381603</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Tomson</surname><given-names>CR</given-names></name><name><surname>Channon</surname><given-names>SM</given-names></name><name><surname>Parkinson</surname><given-names>IS</given-names></name><name><surname>McArdle</surname><given-names>P</given-names></name><name><surname>Qureshi</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>MK</given-names></name><name><surname>Laker</surname><given-names>MF</given-names></name><article-title>Correction of subclinical ascorbate deficiency in patients receiving dialysis: effects on plasma oxalate, serum cholesterol, and capillary fragility</article-title><source>Clin Chim Acta</source><year>1989</year><volume>180</volume><issue>3</issue><fpage>255</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/0009-8981(89)90007-7</pub-id><pub-id pub-id-type="pmid">2743578</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Pru</surname><given-names>C</given-names></name><name><surname>Eaton</surname><given-names>J</given-names></name><name><surname>Kjellstrand</surname><given-names>C</given-names></name><article-title>Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients</article-title><source>Nephron</source><year>1985</year><volume>39</volume><issue>2</issue><fpage>112</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1159/000183353</pub-id><pub-id pub-id-type="pmid">3974772</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Bienfait</surname><given-names>HF</given-names></name><name><surname>van den Briel</surname><given-names>ML</given-names></name><article-title>Rapid mobilization of ferritin iron by ascorbate in the presence of oxygen</article-title><source>Biochim Biophys Acta</source><year>1980</year><volume>631</volume><issue>3</issue><fpage>507</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1016/0304-4165(80)90028-8</pub-id><pub-id pub-id-type="pmid">7407258</pub-id></mixed-citation></ref></ref-list></back></article>